← 返回

靶向 TMED4 通过 IRE1α-自噬轴增强实体瘤中 CD8⁺ T 细胞功能与 CAR-T 细胞疗效

英文原题:Targeting TMED4 enhances CD8(+) T cell function and CAR T cell efficacy in solid tumors through the IRE1α-autophagy axis.

查看英文原题

Targeting TMED4 enhances CD8(+) T cell function and CAR T cell efficacy in solid tumors through the IRE1α-autophagy axis.

PubMed 2026/06/12(内容时间) Sci Adv Q1 · IF 13.9(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

内质网应激(ERS)和自噬可调节肿瘤浸润T细胞功能及耗竭,但相关机制尚不清楚。本研究发现,ERS相关跨膜蛋白TMED4(跨膜emp24结构域蛋白4)是调节CD8⁺ T细胞抗肿瘤免疫的关键因子。T细胞中敲除Tmed4可通过促进CD8⁺ T细胞增殖、浸润及杀伤能力,同时减少终末耗竭,增强抗肿瘤应答。

从机制上看,Tmed4缺失使肌醇需求酶1(IRE1)-X盒结合蛋白1(XBP1)轴过度活化,并以IRE1依赖方式诱导自噬通量。遗传敲除Ern1(IRE1)或Becn1(Beclin1)会削弱Tmed4缺失带来的抗肿瘤效应,凸显ERS和自噬对CD8⁺ T细胞功能的作用。

此外,Tmed4缺失的CAR-T(CAR-T)细胞抗肿瘤免疫能力增强。采用反义寡核苷酸药理性抑制Tmed4,也能增强CD8⁺ T细胞介导的肿瘤控制。

总之,本研究揭示TMED4通过IRE1驱动的自噬调控CD8⁺ T细胞效应功能并限制其终末耗竭,确立TMED4为提高CAR-T 疗效的潜在免疫治疗靶点。

展开英文摘要原文

Endoplasmic reticulum stress (ERS) and autophagy regulate tumor-infiltrating T cell function and exhaustion, but the underlying mechanisms remain unclear.

Here, we identified the ERS-related transmembrane protein TMED4 (transmembrane emp24 domain-containing 4) as a critical regulator of CD8 + T cell antitumor immunity. Tmed4 deletion in T cells enhanced antitumor responses by promoting CD8 + T proliferation, infiltration, and killing capacity, while reducing terminal exhaustion.

Mechanistically, Tmed4 deficiency hyperactivated the inositol-requiring enzyme 1 (IRE1 )-X-box binding protein 1 (XBP1) axis and induced autophagy flux in an IRE1 -dependent manner. Genetic deletion of Ern1 (IRE1 ) or Becn1 (Beclin1) impaired the antitumor effects of Tmed4 deficiency, underscoring the role of ERS and autophagy in CD8 + T cell function.

Moreover, Tmed4 -deficient chimeric antigen receptor T cells (CAR T cells) displayed improved antitumor immunity. Pharmacological inhibition of Tmed4 using antisense oligonucleotide also enhanced CD8 + T cell-mediated tumor control. In summary, our study reveals that TMED4 governs CD8 + T cell effector function and limits terminal exhaustion through IRE1 -driven autophagy, establishing TMED4 as a promising immunotherapeutic target for improving CAR T cell efficacy.

论文信息

作者
Wang H、Shi L、Jiang K、Wu S、Jiang Z、Tao Y、Li J、Li X
单位
Department of General Surgery, Tongren Hospital & Shanghai Institute of Immunology, Center for Immune-Related Diseases Research at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.China
期刊
Science advances2026 Jun 12
原文标识
PubMed 42284413 · DOI 10.1126/sciadv.aee0517